Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary


Karyopharm Therapeutics is owned by 48.37% institutional investors, 6.20% insiders, and 45.43% retail investors. Vanguard group is the largest institutional shareholder, holding 6.12% of KPTI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.71% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics48.37%6.20%45.43%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group7.65M6.12%$5.17M
Adage capital partners gp6.32M5.06%$4.27M
Palo alto investors lp4.91M3.93%$3.32M
Blackrock4.17M3.61%$3.62M
Blackrock funding, inc. /de3.77M3.01%$2.55M
Marshall wace, llp2.40M1.92%$1.63M
Eversept partners, lp2.09M1.67%$1.41M
Avidity partners management lp2.02M1.61%$1.37M
Gsa capital partners llp1.60M1.28%$1.08M
C worldwide group1.50M1.20%$1.01M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Palo alto investors lp4.91M0.51%$3.32M
Birchview capital, lp419.83K0.23%$283.93K
Altium capital management lp740.00K0.14%$500.46K
Avidity partners management lp2.02M0.13%$1.37M
Eversept partners, lp2.09M0.13%$1.41M
Silverarc capital management595.99K0.09%$403.07K
Gsa capital partners llp1.60M0.08%$1.08M
Ubs oconnor1.48M0.08%$1.00M
Ikarian capital408.90K0.04%$276.54K
Velan capital investment management lp40.00K0.02%$27.05K

Top Buyers

HolderShares% AssetsChange
Adage capital partners gp6.32M0.01%2.00M
Jane street group748.31K0.00%543.56K
Susquehanna group, llp664.14K0.00%361.60K
Marshall wace, llp2.40M0.00%319.19K
Ubs oconnor1.48M0.08%287.55K

Top Sellers

HolderShares% AssetsChange
Blackrock4.17M0.00%-5.28M
Eversept partners, lp2.09M0.13%-3.46M
State street453.81K--1.83M
Opaleye management---1.43M
Alphacentric advisors---1.13M

New Positions

HolderShares% AssetsChangeValue
Shay capital172.15K0.02%172.15K$116.43K
Opti capital management, lp125.00K0.00%125.00K$84.54K
Td waterhouse canada48.05K0.00%48.05K$32.19K
Velan capital investment management lp40.00K0.02%40.00K$27.05K
Squarepoint ops20.79K-20.79K$14.06K

Sold Out

HolderChange
Zurcher kantonalbank (zurich cantonalbank)-6.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00
Financial gravity asset management-50.00
Nisa investment advisors-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202492-4.17%60,468,4381.78%482.14%3413.33%24-22.58%
Sep 30, 202496-20.00%59,409,677-12.02%471.39%31-41.51%31-6.06%
Jun 30, 2024120-67,526,761-9.69%581.36%53-7.02%336.45%
Mar 31, 2024120-3.23%74,774,7681.78%651.59%5718.75%31-24.39%
Dec 31, 2023124-1.59%73,464,527-4.85%641.41%48-14.29%4136.67%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv228.10K2.71%22.00
Vanguard US Total Market Shares ETF3.42M2.71%-1.00
Vanguard Explorer Inv2.01M1.59%-
Vanguard Institutional Extnd Mkt Idx Tr109.53K1.30%10.00
C WorldWide Healthcare Select 1A100.00K1.19%10.00
AlphaCentric LifeSci Healthcare I1.13M0.90%-
AlphaCentric Life Sciences & Hlthcare I1.13M0.89%-
Kennedy Micro Cap1.03M0.81%-22.77K
Xtrackers MSCI World Swap ETF 1C712.70K0.56%-
BlackRock Advantage Small Cap Core Instl46.62K0.55%3.00

Recent Insider Transactions


DateNameRoleActivityValue
Apr 04, 2025Paulson Richard A. President and CEOSell$916.30
Mar 04, 2025Mano Michael SVP, General Counsel&SecretarySell$17.57K
Feb 18, 2025Poulton Stuart EVP, Chief Development OfficerSell$3.73K
Feb 04, 2025Paulson Richard A. President and CEOSell$2.66K
Jan 06, 2025Paulson Richard A. President and CEOSell$3.18K

Insider Transactions Trends


DateBuySell
2025 Q1-4
2024 Q4-3
2024 Q3-7
2024 Q2-16
2024 Q1-19

KPTI Ownership FAQ


Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 48.37%, followed by 6.20% insiders and 45.43% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 68.48%, which Karyopharm Therapeutics falls below.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are Vanguard group (7.65M shares, 6.12%), Adage capital partners gp (6.32M shares, 5.06%), and Palo alto investors lp (4.91M shares, 3.93%). Together, they hold 15.10% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

Yes, BlackRock owns 3.61% of Karyopharm Therapeutics, totaling 4.17M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.62M$. In the last quarter, BlackRock decreased its holdings by -5.278M shares, a -55.86% change.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Palo alto investors lp is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.51% of its assets in 4.91M Karyopharm Therapeutics shares, valued at 3.32M$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Karyopharm Therapeutics shares, with 2.71% of its total shares outstanding invested in 228.1K Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools